Royalty Pharma PLC

Royalty Pharma’s $275 million deal with Denali Therapeutics to fund Tividenofusp alfa shows how equity‑linked royalties can accelerate late‑stage biotech launches while sharing upside risk.

Royalty Pharma’s Q2 earnings report reveals a decline in income and valuation concerns, serving as a wake-up call for investors.

Royalty Pharma PLC reported mixed Q2 earnings, with revenue surging but profit declining, but raised its 2025 financial guidance despite the setback.

Royalty Pharma PLC reported strong revenue growth in the second quarter, driven by increased royalty receipts, and has raised its 2025 financial guidance.

Royalty Pharma has announced its third quarter 2025 dividend, solidifying its position as a major player in the pharmaceutical industry with a strong stock price and financial metrics.

Royalty Pharma continues to demonstrate its commitment to growth and transparency through dividend payments, new board appointments, and upcoming financial results.

Royalty Pharma has entered into a definitive agreement to acquire Revolution Medicines’ cancer drug for up to $2 billion, marking a significant milestone in the company’s efforts to expand its portfolio and invest in cutting-edge treatments.

Royalty Pharma has agreed to acquire Revolution Medicines’ cancer drug for up to $2 billion.

Royalty Pharma’s stock price closed at $35.4 USD, with a relatively stable performance and a 52-week price range of $24.05 to $35.455 USD.

Royalty Pharma’s stock price appears stable, but a closer look at the numbers reveals a more complex picture, with moderate valuation and volatility raising cautionary flags for investors.